Key Players
Competitive Landscape
NICU modular nutrition market includes integrated infant nutrition companies and specialist human milk-based product companies. Abbott and Danone Nutricia are focusing on broader fortification and protein product ranges. Prolacta Bioscience and Medolac Laboratories provides human milk-based products for vulnerable infants. Mead Johnson / Reckitt and Nestle S.A. participate through established infant nutrition portfolios and hospital distribution. Hospitals compare nutrient concentration, preparation requirement, sterile format and feed compatibility before adding a product. Companies having liquid formats and clear dosing instruction are expected to receive higher preference among neonatal units.
During 2025 and 2026, company focus moved toward product continuity, country approval and local clinical evidence. Danone Nutricia retained the same Nutriprem formulations during its UK brand change in July 2025. Prolacta Bioscience received Japan approval for PreemieFort in February 2026 and reported JASMINE results in April 2026. Health Canada also continued access to two Mead Johnson liquid fortifiers in July 2026. These developments are expected to support product availability and hospital use during the forecast period.
NICU modular nutrition development map, 2026 to 2036
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| July 2026: Health Canada retained Mead Johnson liquid fortifiers in the transition list. | Specialty infant nutrition requires continued hospital product supply. | Regulatory transition is increasing focus on continued hospital product availability. | Continued access is expected to support existing hospital use. |
| April 2026: Prolacta reported JASMINE results from 11 Japanese NICUs. | Hospitals requires local clinical evidence before changing neonatal feeding protocol. | Companies are using country-specific clinical data for hospital market entry. | Local evidence can support product use in additional Japanese NICUs. |
| February 2026: Japan approved PreemieFort as a prescription medicine. | Vulnerable infants requires controlled product quality and hospital distribution. | Human milk-based fortification has entered prescription medicine route in Japan. | Prescription route is expected to support controlled hospital access. |
| July 2025: Danone Nutricia began the Aptamil Nutriprem brand transition. | Neonatal units requires product continuity when brand and packaging changes. | Companies are increasing hospital communication during product brand changes. | Clear transition information can reduce disruption in hospital product ordering. |
Source: Future Market Insights, NICU Modular Nutrition Market Report, 2026-2036.
Abbott, Danone Nutricia, Mead Johnson / Reckitt, and Nestle S.A. compete through broad hospital and infant-nutrition access. Prolacta Bioscience and Medolac Laboratories compete through specialist human milk-based fortification platforms.
Who leads the NICU modular nutrition market?
Abbott, Prolacta Bioscience, Danone Nutricia, Mead Johnson / Reckitt, Nestle S.A., and Medolac Laboratories have products related with neonatal fortification. Company position differs by neonatal product range, hospital access and country availability.
What should hospital buyers evaluate before approval?
Hospitals requires product indication, nutrient concentration, sterility, storage, feed compatibility and clear dosing instruction before approval. Continued product supply and staff preparation requirement also influence hospital selection.
How may competition change through 2036?
Competition is expected to increase through country-specific clinical evidence, liquid product formats and wider hospital distribution. Products having simple preparation and precise dosing are likely to receive higher NICU use through 2036.
Representative Company Overview
| Company | Current position | Verified portfolio or development |
|---|---|---|
| Abbott | Integrated neonatal nutrition | Liquid Protein Fortifier is used with human milk, fortified human milk or formula. |
| Prolacta Bioscience | Human milk-based fortification | Japan approved PreemieFort in February 2026 and JASMINE results were reported in April 2026. |
| Danone Nutricia | Preterm fortification and modular nutrition | The UK Nutriprem range retained its protein supplement and human milk fortifier during brand change. |
| Mead Johnson / Reckitt | Integrated infant nutrition | Two liquid human milk fortifiers remained in the Health Canada transition list in July 2026. |
| Nestle S.A. | Hospital infant nutrition | The company offers PreNAN human milk fortifier in selected markets. |
| Medolac Laboratories | Human milk specialty platform | FortifyMVP is a human milk-based fortifier intended for NICU use. |
Research Methodology
The companies included in the report represents direct neonatal fortification, human milk-based products and hospital infant nutrition portfolios. Desk research covers government publication, clinical guidance, regulatory records, company announcements and product documentation.
